Company behind diabetes management breakthrough sponsors Insulin Safety Week 2025
The company behind a pioneering device that significantly improves diabetes self-management will sponsor next month’s Insulin Safety Week 2025.
Designed to simplify the handling and storage of insulin pen needles, NeedleBay provides an innovative solution for safe and efficient insulin administration. Research has shown that users experienced an 88 per cent improvement in managing their diabetes medication, with an overall 79 per cent improvement in managing diabetes medication and a 94 per cent improvement in its safe delivery.
By securely storing and organising insulin pen needles, NeedleBay ensures greater control over medication, promotes single-use practices and provides clear proof of use, supporting people living with diabetes to manage their condition safely and effectively.
Perfect for those on the go, the latest version of the device has been developed in response to user feedback, further enhancing its ability to simplify insulin administration, prevent missed doses and reduce the risk of accidental needlestick injuries.
By supporting Insulin Safety Week 2025 to continue its vital mission to raise awareness of insulin safety, NeedleBay will help healthcare professionals better understand how innovation can improve patient outcomes.
Peter Brenikov, Director, NeedleBay, said: “We are delighted to sponsor Insulin Safety Week 2025, an important event that brings healthcare professionals together to strengthen their knowledge of insulin therapy, improve patient outcomes and minimise risks.
“At NeedleBay, we are committed to providing solutions that support safe and effective diabetes management and we are excited to see how this year’s campaign will drive further improvements in insulin safety.”
Insulin Safety Week will be held May 12 to 18, for further information please visit www.insulinsafetyweek.com
For more information about NeedleBay visit www.needlebay.com
Insulin Safety Week 2025 has been funded by embecta, D&H Food and Nutrition Limited, NeedleBay and Sanofi who have had no input into any arrangements or content.